Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center’s experience
While the per-protocol DeLOS-II results earlier reported comparable 24-month LFS and OS in arms A and B, our subcohort's long-term follow-up data demonstrate a superior 125-month outcome in arm B.
Authors
- Theresa Wald (ORCID: https://orcid.org/0000-0002-7602-1743)
- Susanna Wiegand (ORCID: https://orcid.org/0000-0001-8341-9533)
- Matthaeus Stoehr (ORCID: https://orcid.org/0000-0003-4219-4459)
- Markus Pirlich (ORCID: https://orcid.org/0000-0002-8581-0453)
- Veit Zebralla (ORCID: https://orcid.org/0000-0001-5519-7566)
- Viktor Kunz (ORCID: https://orcid.org/0000-0002-2415-7841)
- Gunnar Wichmann (ORCID: https://orcid.org/0000-0001-6191-2095)
- Andreas Dietz (ORCID: https://orcid.org/0000-0001-8254-1676)
Institutions
- Christian-Albrechts-Universität zu Kiel (DE)
- University Hospital Schleswig-Holstein (DE)
- University Hospital Leipzig (DE)
- Leipzig University (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.3389/fonc.2024.1506840
- Citations
- 1
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.58
Funders
- Universität Leipzig